Publication planning 101: A report

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 12, Issue 3, 2009, Pages 273-279

  Sismondo, Sergio ^a   Nicholson, Scott Howard ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; CHLOROTHIAZIDE;

ARTICLE; CONSUMER HEALTH INFORMATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG RESEARCH; HEALTH CARE PLANNING; MEDICAL LITERATURE; MEDICAL SOCIETY; PRODUCT DEVELOPMENT; PUBLICATION; PUBLISHING; STRATEGIC PLANNING; CLINICAL TRIAL; ECONOMICS; HUMAN; MARKETING; MEDICAL RESEARCH; METHODOLOGY; PEER REVIEW; PUBLIC RELATIONS; STANDARD; WRITING;

AUTHORSHIP; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; EDITORIAL POLICIES; HUMANS; INTERPROFESSIONAL RELATIONS; MARKETING; PEER REVIEW, RESEARCH; PERIODICALS AS TOPIC; PUBLISHING;

EID: 77950353859     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3ww2r     Document Type: Article

References (26)

1. Healy, D. and D. Cattell, Interface between authorship, industry and science in the domain of therapeutics. British Journal of Psychiatry, 2003. 183: p. 22-27.
2. Matheson, A., Corporate Science and the Husbandry of Scientific and Medical Knowledge by the Pharmaceutical Industry. BioSocieties, 2008. 3: p. 355-382.
3. Sismondo, S., Ghost management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Medicine, 2007. 4(9): p. e286.
4. Sismondo, S., Ghosts in the Machine: Publication Planning in the Medical Sciences. Social Studies of Science, 2009. 39(2): p. 171-98.
5. Steinman, M.A., et al., Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents. Annals of Internal Medicine, 2006. 145(4): p. 284-93.
6. Greene, J.A. Prescribing by Numbers: Drugs and the Definition of Disease. 2007. Johns Hopkins University Press.
7. World Health Organization, The World Medicines Situation. 2004: Geneva.
8. Mittra, J., Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour of Large Firm. Technology Analysis and Strategic Management, 2007. 19(3): p. 279-301.
9. Mirowski, P. and R. Van Horn, The Contract Research Organization and the Commercialization of Scientific Research. Social Studies of Science, 2005. 35: p. 503-534.
10. Innovex. http://www.innovex.com/default.htm. 2009 (cited Mar. 3, 2009); Available from: http://www.innovex.com/default.htm.
11. Watermeadow Medical. http://www.watermeadowmedical.com/. 2009 (cited Mar. 3, 2009).
12. Envision Pharma, http://www.envisionpharma.com/publicationsPlanning/. 2009.
13. Ross, J.S., et al., Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation. JAMA, 2008. 299(15): p. 1800-1812.
14. U.S. Department of Justice. Warner-Lambert to Pay $430 Million to Resolve Criminal & Civil Health Care Liability Relating to Off-Label Promotion. 2006 (cited 14 March, 2009); Available from: http://www.usdoj.gov/opa/pr/2004/May/04_civ_322.htm.
15. ISMPP. Code of Ethics. 2008. Available at http://www.ismpp.org/ (cited September 2009).
16. Wager, E., et al., Good Publication Practice for Pharmaceutical Companies. CMRO, 2003. 19(3): p. 149-154.
17. Gardiner-Caldwell Group. http://www.thgcgroup. com/. 2007 (cited November 2007); Available from: http://www.thgc-group.com/.
18. Oldani, M., Thick Prescriptions: Toward an Interpretation of Pharmaceutical Sales Practices. Medical Anthropology Quarterly, 2004. 18(3): p. 325-356.
19. ICMJE. International Committee of Medical Journal Editors uniform requirments for manuscripts submitted to biomedical journals. 2005 (cited; Available from: http://www.icjme.org.
20. Gøtzsche, P.C., et al., Ghost Authorship in Industry-Initiated Randomised Trials. PLOS Medicine, 2007. 4(1): p. 47-52.
21. Moffatt, B. and C. Elliott, Ghost Marketing: Pharmaceutical Companies and Ghostwritten Journal Articles. Perspectives in Biology and Medicine, 2007. 50(1): p. 18-31.
22. Finucane, T. and C. Boult, Association of funding and findings of pharmaceutical research at a meeting of a medical professional society. JAMA, 2004. 117: p. 842-5.
23. Smith, R., Lapses at the New England Journal of Medicine. Journal of the Royal Society of Medicine, 2006. 99(8): p. 380-382.
24. Lexchin, J. and D. Light, Commercial influence and the content of medical journals. BMJ, 2006. 332: p. 1444-1447.
25. Grant, B. Merck Published Fake Journal. TheScientist. com. April 30, 2009.
26. PhRMA. Pharmaceutical Marketing in Perspective: Its Value and Role as One of Many Factors Informing Prescribing. 2009 (cited Mar. 3, 2009); Available from: http://www.phrma.org/files/PhRMA%20Market ing%20Brochure%20Influences%20on%20Pres cribing%20FINAL.pdf.